Evaluation of Lactococcus lactis carrying active For t 2 protein in immunotherapy for Forcipomyia taiwana allergy in mice
The results imply that mucosal allergen-specific immunotherapy of <i>L. lactis</i> For t 2 is a better cost-effective alternative to conventional subcutaneous allergen-specific immunotherapy. This study shows that non-viable <i>L. lactis</i>-derived For t 2 active protein may be a promising therapeutic for treating midge allergy.
Authors
- Mey-Fann Lee (ORCID: https://orcid.org/0009-0002-6303-3363)
- Nancy M. Wang (ORCID: https://orcid.org/0000-0002-8836-812X)
- Chi‐Sheng Wu (ORCID: https://orcid.org/0000-0002-6514-8677)
- Yi‐Hsing Chen (ORCID: https://orcid.org/0000-0002-8135-9554)
- Chu-Hui Chiang
Institutions
- National Pingtung University of Science and Technology (TW)
- Taichung Veterans General Hospital (TW)
- National Changhua University of Education (TW)
Publication Details
- Journal
- World Allergy Organization Journal
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.waojou.2025.101073
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taichung Veterans General Hospital